Literature DB >> 23864171

Biologic treatments for adult-onset Still's disease.

Ibrahim A Al-Homood1.   

Abstract

Adult-onset Still's disease (AOSD) is a systemic inflammatory disorder that is a diagnosis of exclusion. It is characterized by high spiking fevers, arthritis or arthralgia, and an evanescent salmon-coloured rash. Many other systemic manifestations and laboratory test abnormalities may occur. Biologic drugs, TNF-α inhibitors, and IL-1 and IL-6 blockers have been used for the treatment of patients with AOSD refractory to conventional treatment or those with life-threatening manifestations aiming for better disease control. Data on biologic treatments in AOSD are limited and consist mainly of case reports, small case series and retrospective studies. Using biologic agents (anti-TNF-α, anti-IL-1 and anti-IL-6) with traditional immunosuppressive drugs resulted in significant improvement of disease outcomes. IL-1 and IL-6 inhibitors seem to be more efficient than TNF-α inhibitors.

Entities:  

Keywords:  TNF-α inhibitor; abatacept; adult-onset Still’s; anakinra; canakinumab; rituximab; tocilizumab

Mesh:

Substances:

Year:  2013        PMID: 23864171     DOI: 10.1093/rheumatology/ket250

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  16 in total

1.  Pulmonary aspergillosis after treatment with infliximab in Still's disease and a literature review of Still's disease and pulmonary aspergillosis.

Authors:  Emrah Şeyhoğlu; Abdülsamet Erden; Levent Kılıç; Ömer Karadağ; Sevtap Arıkan Akdağlı; Ali Akdoğan; Umut Kalyoncu
Journal:  Eur J Rheumatol       Date:  2018-03

Review 2.  Adult-Onset Still's Disease: Molecular Pathophysiology and Therapeutic Advances.

Authors:  Paolo Sfriso; Sara Bindoli; Paola Galozzi
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

Review 3.  [Still's disease in children and adults].

Authors:  C M Hedrich; C Günther; M Aringer
Journal:  Z Rheumatol       Date:  2017-09       Impact factor: 1.372

Review 4.  [Still's disease in children and adults].

Authors:  C M Hedrich; C Günther; M Aringer
Journal:  Hautarzt       Date:  2017-06       Impact factor: 0.751

Review 5.  Progress in Biological Therapies for Adult-Onset Still's Disease.

Authors:  Paola Galozzi; Sara Bindoli; Andrea Doria; Paolo Sfriso
Journal:  Biologics       Date:  2022-04-21

6.  TRACHEOSTOMY: WE NEED TO KNOW A HOLE LOT MORE.

Authors:  Brian Purcell; Philip R Bell; Rosemary Stewart
Journal:  Ulster Med J       Date:  2015-05

Review 7.  Adult-onset Still's disease: current challenges and future prospects.

Authors:  Mariam Siddiqui; Michael S Putman; Anisha B Dua
Journal:  Open Access Rheumatol       Date:  2016-03-15

8.  Refractory Adult Onset Still's Disease.

Authors:  Wahinuddin Sulaiman; Aris Chandran Abdullah; Jerome Tan Tsen Chuen; Shaffie Baba; Norain Karim
Journal:  Cureus       Date:  2017-10-25

9.  Successful Tocilizumab Therapy for Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease: A Case-Based Review.

Authors:  Eri Watanabe; Hitoshi Sugawara; Takeshi Yamashita; Akira Ishii; Aya Oda; Chihiro Terai
Journal:  Case Rep Med       Date:  2016-09-05

10.  Successful Treatment with Intravenous Cyclophosphamide for Refractory Adult-Onset Still's Disease.

Authors:  Yoshika Tsuji; Nozomi Iwanaga; Anna Adachi; Kinuyo Tsunozaki; Yasumori Izumi; Yuji Moriwaki; Kazuhiro Kurohama; Masahiro Ito; Atsushi Kawakami; Kiyoshi Migita
Journal:  Case Rep Rheumatol       Date:  2015-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.